Recent

% | $
Quotes you view appear here for quick access.

The Madison Square Garden Company Message Board

feoli2003 126 posts  |  Last Activity: 18 hours ago Member since: Jul 21, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • feoli2003 feoli2003 18 hours ago Flag

    Thats a bit risky. They are not the only players here…this is global market and anyone could snap those share up at anytime.

  • feoli2003 feoli2003 18 hours ago Flag

    Funny thing is that the buyer who is so willing to buy at $.47 and $.475 passes up a juicy 49,000 share block for $.015 cents more??? If I was accumulating that many shares, $.015 on a large block would make no difference.

  • feoli2003 feoli2003 Feb 11, 2016 4:33 PM Flag

    saw that too..before last week the trades would show up after the close. Now they take place before the close, but don't show up on the thread. ????

  • feoli2003 feoli2003 Feb 11, 2016 12:58 PM Flag

    Which facility did you call? Telephone number?

  • Interesting that it did not show up as a trade? I think its the 49,100 share block that is showing at $.4999.
    Final volume once again over 100K

  • Reply to

    Who is selling into the huge bid blocks?

    by feoli2003 Feb 9, 2016 10:40 AM
    feoli2003 feoli2003 Feb 9, 2016 10:48 AM Flag

    When this stock will be trading at $4-5 in the near future, whoever sold in this range will regret it dearly.

  • Can't you see that you losing potentially much higher gains by not waiting for bids to rise. Unless you have margin calls on your other stocks, there should be no reason for anyone to sell now. Someone is accumulating in a major way and price will have to rise..can't stay at $.50 much longer.

  • Reply to

    chances

    by brazel.matthew Feb 8, 2016 10:45 AM
    feoli2003 feoli2003 Feb 8, 2016 12:17 PM Flag

    Yes, you are right. It was a 50 Million share or so added to the 80 million shares outstanding, 39% of which is owned by insiders.

  • Reply to

    chances

    by brazel.matthew Feb 8, 2016 10:45 AM
    feoli2003 feoli2003 Feb 8, 2016 11:13 AM Flag

    I don't expect any significant revenue from the financials except for share count; That is what people want to know. 125 million is the amount people are counting for. Once we get this number proper valuations can be placed for the company.

  • Having the overall market selloff will only amplify the rise of IVOB in the coming weeks as people are searching for places to invest. A few up days in this environment will draw more and more attention to the stock. We are getting closer and closer to major news announcements…counting the days!!!

  • at 4:07

  • Clogging the ask at $.50 has got to end soon…Its obvious someone wants the shares cheap. One good day of buying should break us through.

  • feoli2003 feoli2003 Feb 2, 2016 2:34 PM Flag

    Part 3:Multiple Rate [ Time Frame: Measures assessed 9 months after the last subject received an embryo transfer, once all live birth data is known for each embryo. ] [ Designated as safety issue: No ]
    Multiple rate: Number cycles with twins or triplets divided by the number of cycles with embryo transfers

    Enrollment: 40
    Study Start Date: January 2013
    Study Completion Date: January 2016
    Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
    Arms Assigned Interventions
    Medical Device: INVOcell Culture Device
    5 day oocyte incubation using INVOcell Culture Device within the vaginal cavity.
    Device: INVOcell Culture Device
    INVOcell is a vaginal culture device
    Other Name: INVOcell, INVOcell Culture Device
    Active Comparator: Medical Device: IVF Incubator
    5 day oocyte incubation using traditional IVF incubation.
    Device: IVF Incubation
    IVF Incubator

    Detailed Description:
    This is a Phase III, single center, open label randomized comparative trial to evaluate intravaginal culture using INVOcell vs. traditional IVF to generate day 5 embryos Pilot: 40 couples (80 patients), randomized to receive either intravaginal culture (n=20) using the INVOcell or traditional IVF (n=20) Primary Endpoints: Blastocyst generation rate: number of day 5 embryos of "good quality" defined as 2BB or greater (expansion of embryo 2,3,4,5 or 6 and inner cell mass and outer cell mass grades of A or B) or higher using the Gardner Grading System divided by the number of eggs incubated Patient acceptability of INVOcell and intravaginal culture.

    Secondary Endpoints: Live birth rate: number of cycles with a live birth divided by the number of cycles with embryo transfers.

    Clinical pregnancy rate: number of cycles with fetal heartbeat at week 7 divided by the number of cycles with embryo transfers.

    Fertilization rate: Number of embryos obtained after incubation divided by the number of oocytes placed in the device.

    Embryo transfer rate: Number of cycles initiated divided by the number of cycles with embryo transfers Miscarriage rate: Number of miscarriages divided by the number of cycles with embryo transfers Multiple rate: Number cycles with twins or triplets divided by the number of cycles with embryo transfers Miscarriage rate per clinical pregnancy: Number of miscarriages divided by the number of cycles with clinical pregnancy

    Eligibility

    Ages Eligible for Study: 18 Years to 38 Years
    Genders Eligible for Study: Both
    Accepts Healthy Volunteers: Yes
    Criteria
    Inclusion Criteria:

    Couples who will participate to the study will be pre selected for the following major indications:

    Women diagnosed with:

    Tubal factor
    Endometriosis (type I to II)
    Ovulatory dysfunction (slight)
    Multiple female factors ( 1 or 15 million total motile spermatozoa with normal morphology or borderline normal morphology ( 3% with the strict criteria) and a progression rating of 2.
    Exclusion Criteria:

    Women to be excluded from this study are those who have:

    Inability to read and speak English fluently
    A history of recurrent vaginitis
    A history of toxic shock syndrome
    Known allergies to plastic, human serum proteins or gentamicin
    Had pelvic surgery within the past 8 weeks, excluding diagnostic laparoscopy
    Pelvic inflammatory disease (PID) within the past 3 months and were treated with antibiotics
    Severe endometriosis (stage III-IV) or endometriomas (past or present)
    Clinical signs of vaginal infection
    Significant abnormalities of the vaginal cavity
    Sub mucus or intramural fibroids ( 1 cm diameter)
    Hydrosalpinx
    Chronic illness, e.g. autoimmune disease, diabetes
    BMI 36
    Donor oocytes, donor sperm
    antral follicle count 20
    Anti-Mullerian Hormone 3
    Previously responded poorly to ovarian stimulation and polycystic ovary patients
    High responder to ovarian stimulation
    Cervical stenosis, as demonstrated by failed mock embryo transfer
    Cannot tolerate a speculum examination
    Unwilling or unable to wear a retention system (diaphragm) during the 5 days of incubation. ➢ 2 previously failed IVF (neg βhCG)
    Previously failed fertilization of all oocytes previous IVF cycle
    Smoke or abuse drugs and alcohol
    Poor understanding of the procedure
    Partner with vasectomy reversal
    Partner with difficulty in producing sperm specimen
    Partner with uro-genital infection. Sperm culture will be performed if the partner shows or has shown some symptoms of uro-genital infection.
    Contacts and Locations
    Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

    Please refer to this study by its ClinicalTrials.gov identifier: NCT02363426

    Locations
    United States, Texas
    C.A.R.E.
    Beford, Texas, United States
    Sponsors and Collaborators
    Invaron Pharmaceuticals Inc.
    More Information

    Publications:
    Ranoux C, Aubriot FX, Dubuisson JB, Cardone V, Foulot H, Poirot C, Chevallier O. A new in vitro fertilization technique: intravaginal culture. Fertil Steril. 1988 Apr;49(4):654-7.

    Responsible Party: Invaron Pharmaceuticals Inc.
    ClinicalTrials.gov Identifier: NCT02363426 History of Changes
    Other Study ID Numbers: CP-006
    Study First Received: February 5, 2015
    Last Updated: January 18, 2016
    Health Authority: United States: Food and Drug Administration
    United States: Institutional Review Board

    Keywords provided by Invaron Pharmaceuticals Inc.:
    intravaginal culture
    in vitro fertilization
    blastocyst
    pregnancy

    ClinicalTrials.gov processed this record on February 01, 2016

  • feoli2003 feoli2003 Feb 2, 2016 12:10 PM Flag

    part 2:Secondary Outcome Measures:
    Patient Acceptability [ Time Frame: Measures assessed at first followup visit following embryo transfer, approximately 9 weeks post randomization ] [ Designated as safety issue: No ]
    Patient acceptability of INVOcell and intravaginal culture using a 12 point subjective and quantitative questionnaire.

    Live Birth Rate [ Time Frame: Measures assessed 9 months post embryo transfer, approximately 9 months and two weeks following randomization ] [ Designated as safety issue: No ]
    Live birth rate: number of cycles with a live birth divided by the number of cycles with embryo transfers.

    Clinical Pregnancy Rate [ Time Frame: Measures assessed approximately 16 days following embryo transfer, approximately 4 weeks following randomization. ] [ Designated as safety issue: No ]
    Clinical pregnancy rate: number of cycles with fetal heartbeat at week 7 divided by the number of cycles with embryo transfers.

    Fertilization Rate [ Time Frame: Measures assessed following 5 days post incubation, approximately 2 and 1/2 weeks post randomization. ] [ Designated as safety issue: No ]
    Fertilization rate: Number of embryos obtained after incubation divided by the number of oocytes placed in the device.

    Embryo Transfer Rate [ Time Frame: Measures assessed following 5 days incubation, approximately 2 and 1/2 weeks following randomization. ] [ Designated as safety issue: No ]
    Embryo transfer rate: Number of cycles initiated divided by the number of cycles with embryo transfers

    Miscarriage Rate [ Time Frame: Measures assessed following embryo transfer and a maximum of 9 months gestation. ] [ Designated as safety issue: No ]
    Miscarriage rate: Number of miscarriages divided by the number of cycles with embryo transfers

    Multiple Rate [ Time Frame: Measures assessed 9 months after the last subject received an embryo transfer, once all live birth data is known for each embryo. ] [ Designated as safety issue: No ]
    Multiple rate: Number cycles with twins or triple

  • Take a look at clinical trials(dot)gov
    Looks like the trial was finished in January 2016.
    Here is a portion of the info:
    Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation
    This study has been completed.
    Sponsor:
    Invaron Pharmaceuticals Inc.
    Information provided by (Responsible Party):
    Invaron Pharmaceuticals Inc.
    ClinicalTrials.gov Identifier:
    NCT02363426
    First received: February 5, 2015
    Last updated: January 18, 2016
    Last verified: January 2016
    History of Changes
    Full Text View Tabular ViewNo Study Results PostedDisclaimerHow to Read a Study Record
    Purpose
    The purpose of this study is to evaluate intravaginal culture using the medical device INVOcell to generate day 5 blastocysts in comparison to traditional IVF.

    Condition Intervention Phase
    Infertility
    Device: INVOcell Culture Device
    Device: IVF Incubation
    Phase 3

    Study Type: Interventional
    Study Design: Allocation: Randomized
    Endpoint Classification: Safety/Efficacy Study
    Intervention Model: Parallel Assignment
    Masking: Open Label
    Primary Purpose: Treatment
    Official Title: Randomized Controlled Open-Label Non-Inferiority Trial Comparing Day 5 Embryos Derived From Intravaginal Culture Using the Medical Device INVOcell to Traditional In Vitro Fertilization

    Further study details as provided by Invaron Pharmaceuticals Inc.:

    Primary Outcome Measures:
    Blastocyst Quality [ Time Frame: Measures assessed following 5 days incubation, approximately 17 days following randomization ] [ Designated as safety issue: No ]
    Blastocyst generation rate: number of day 5 embryos of "good quality" defined as 2BB or greater (expansion of embryo 2,3,4,5 or 6 and inner cell mass and outer cell mass grades of A or B) or higher using the Gardner Grading System divided by the number of eggs incubated

    Secondary Outcome Measures:
    Patient Acceptability [ Time Frame: Measures assessed at first followup visit following embryo transfer, approximately 9 weeks post randomization ] [ Designated as safety issue: No ]
    Patient

  • Reply to

    February should be more interesting

    by feoli2003 Jan 30, 2016 6:00 PM
    feoli2003 feoli2003 Jan 31, 2016 5:13 PM Flag

    To you doctor boy, it may mean nothing but to others it means something. You have contributed absolutely nothing to this board since you have started posting, zero, except your boasting on how many shares you have. Why don't you post something interesting, since you are a doctor; maybe a peer review article or something. Some of us are not doctors, but follow the technical movements of shares. 13.5 Million shares does mean something, its about 20% of the float of 76 Million (125 Million outstanding - 39% insider = 76Million.) Most of those shares will not get back on the market for a while. In the past also, if you follow the share count in the past 4 years, every 10 Million shares traded dried up the market in that trading range and we made a technical upwards advance. We are due for one anytime, regardless of news coming out next week or next month.

  • Reply to

    February should be more interesting

    by feoli2003 Jan 30, 2016 6:00 PM
    feoli2003 feoli2003 Jan 31, 2016 1:07 PM Flag

    How's this for accurate: 13,475,900 shares traded since FDA approval. What have you contributed since you have been on this board, absolutely nothing.

  • than January….as we get closer to NEWS!

  • Reply to

    BOOM!! The dump continues.

    by worldwide14u Jan 29, 2016 4:14 PM
    feoli2003 feoli2003 Jan 29, 2016 5:46 PM Flag

    These are AH trade settlements…or T trades. I don't think I need to explain. In any case they are unregistered trades done by the likes of you MM's, who have to balance the trades at the end of the trading session. In any case the more volume the better. One of these days, you will get caught with your pants down and a big dk will be rammed up your behind, exactly what you deserve..but maybe you like that.

MSG
151.58-0.36(-0.24%)Feb 12 4:02 PMEST